The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset
NCT ID: NCT05713136
Last Updated: 2024-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
40000 participants
OBSERVATIONAL
2023-01-25
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What proportion of the participants that have been diagnosed with HCV infection have started treatment when their records are reviewed 12 weeks after diagnosis?
Participants will have one in-person visit where they will provide informed consent and receive a finger-prick rapid result test for Hepatitis C infection. Participants with no previous Hepatitis C infection will have a screening test to see if they have an immune reaction to Hepatitis C. Participants who know they have been infected with Hepatitis C in the past, and all participants with a positive screening test result will then be given a Hepatitis C diagnostic test at this visit.
No treatment is provided as a part of this study, participants who are diagnosed with Hepatitis C infection will be referred to testing locations standard of care for any additional clinical assessments and treatment initiation. A review of the participant's records will be made 12 weeks after their Hepatitis C result and their treatment data are gathered.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The National Australian HCV Point-of-Care Testing Program
NCT05042544
The National Australian HCV Point-of-Care Testing Program - Minimal Dataset
NCT05248555
Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)
NCT05016609
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
NCT02065999
Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Programs
NCT04014179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People at risk of HCV acquisition
Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing
Diagnostic Test: Point-of-Care Testing
Participants will be offered finger-stick point-of-care testing for HCV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnostic Test: Point-of-Care Testing
Participants will be offered finger-stick point-of-care testing for HCV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years of age.
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Flinders University
OTHER
Kirby Institute
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ACT Justice Health
Canberra, Australian Capital Territory, Australia
Justice Health and Forensic Mental Health Network
Sydney, New South Wales, Australia
Queensland Injectors Health Network Ltd
Bowen Hills, Queensland, Australia
West Moreton Hospital and Health Service
Brisbane, Queensland, Australia
Lotus Glen Correctional Centre
Cairns, Queensland, Australia
Townsville Correctional Centre
Townsville, Queensland, Australia
Woodford Correctional Centre
Woodford, Queensland, Australia
South Australian Prison Health Service
Adelaide, South Australia, Australia
Hepatitis South Australia
Hackney, South Australia, Australia
Tasmanian Prison Service
Hobart, Tasmania, Australia
St Vincent's Hospital (Melbourne)
Melbourne, Victoria, Australia
WA Department of Justice
Perth, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Alex Misev
Role: primary
Tracey Brown
Role: primary
Nik Alexander
Role: primary
Blake Ponting
Role: primary
Darren Russell
Role: primary
John Morey
Role: primary
Rajendra Prakash
Role: primary
Tom Turnbull
Role: primary
Lisa Carter
Role: primary
Deborah Siddell
Role: primary
Alex Thompson
Role: primary
Holly Beasley
Role: primary
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VHCRP2203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.